1.
Gynecol Oncol
; 183: 78-84, 2024 Apr.
Article
in English
| MEDLINE
| ID: mdl-38554477
ABSTRACT
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been retracted at the request of the Authors. The authors have independently identified an error in the formula that was utilized to calculate the Quality Adjusted Life Years which invalidates the data and the conclusion of the paper. The authors have contacted the journal requesting to retract the article. Apologies are offered to the readers of the journal for any confusion or inconvenience that may have resulted from the publication of this article.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Cost-Benefit Analysis , Endometrial Neoplasms , Neoplasm Recurrence, Local , Humans , Female , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/economics , Neoplasm Recurrence, Local/economics , Neoplasm Recurrence, Local/drug therapy , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Middle Aged , Aged , Antibodies, Monoclonal, Humanized/economics , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Quality-Adjusted Life Years
2.